Elotuzumab is a First-in-Class monoclonal antibody directed against the SLAMF7 receptor, it specifically binds to signaling lymphocyte activating molecule family member 7 (SLAMF7) and activates the bodys immune response to attack and kill multiple myeloma cells. Elotuzumab exerts its anti-myeloma effects mainly through ADCC and activation of NK cells.
Purity:
>98.0%
CAS Number:
[915296-00-3]
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted